US clears new option for gastroenteropancreatic tumours
admin 29th January 2018 Uncategorised 0US regulators have cleared the use of Novartis group Advanced Accelerator Applications’ Lutathera to treat certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
More: US clears new option for gastroenteropancreatic tumours
Source: News